Diffusion Pharmaceuticals (NASDAQ:DFFN) Research Coverage Started at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFNGet Rating) in a note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright upgraded Diffusion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $9.50 price target on the stock in a research report on Tuesday, August 16th.

Diffusion Pharmaceuticals Price Performance

Shares of Diffusion Pharmaceuticals stock opened at $5.76 on Friday. The business’s fifty day moving average price is $6.78 and its two-hundred day moving average price is $11.21. The company has a market capitalization of $11.74 million, a P/E ratio of -0.47 and a beta of 1.53. Diffusion Pharmaceuticals has a 1-year low of $5.10 and a 1-year high of $26.25.

Diffusion Pharmaceuticals (NASDAQ:DFFNGet Rating) last announced its earnings results on Thursday, August 11th. The company reported ($2.06) earnings per share for the quarter, missing the consensus estimate of ($1.77) by ($0.29). On average, research analysts expect that Diffusion Pharmaceuticals will post -8.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Diffusion Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in shares of Diffusion Pharmaceuticals during the 1st quarter valued at $106,000. Trexquant Investment LP acquired a new position in shares of Diffusion Pharmaceuticals during the 2nd quarter valued at $71,000. Finally, Renaissance Technologies LLC increased its position in shares of Diffusion Pharmaceuticals by 8.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company’s stock valued at $331,000 after purchasing an additional 101,100 shares during the period. 10.25% of the stock is currently owned by institutional investors and hedge funds.

About Diffusion Pharmaceuticals

(Get Rating)

Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.

Read More

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.